Part A: Safusidenib Erbumine Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Part A: Safusidenib Erbumine comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Astrocytoma. Most recent publication: Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial., Nat Med, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.
    Drummond KJ, Spiteri M, Cain SA, et al. · Nat Med · 2025
    PubMed: PMID 40841487 · NCT05577416 (AB-218-IIT-201) · Astrocytoma
  2. A perioperative study of Safusidenib in patients with IDH1-mutated glioma.
    Cain SA, Topp M, Rosenthal M, et al. · Future Oncol · 2024
    PubMed: PMID 39140289 · NCT05577416 (AB-218-IIT-201) · Astrocytoma

Publications by year

2024–2025: 2 publications.

2024
1
2025
1

Publications by indication

Astrocytoma (2)

  • Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.
    Nat Med · 2025 · PMID 40841487 · NCT05577416
  • A perioperative study of Safusidenib in patients with IDH1-mutated glioma.
    Future Oncol · 2024 · PMID 39140289 · NCT05577416

Publications by journal

  • Nat Med1 paper
  • Future Oncol1 paper

All Part A: Safusidenib Erbumine publications (2)

2025 (1 paper)

  1. Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.
    Drummond KJ, Spiteri M, Cain SA, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40841487 · NCT05577416 (AB-218-IIT-201) · Astrocytoma

2024 (1 paper)

  1. A perioperative study of Safusidenib in patients with IDH1-mutated glioma.
    Cain SA, Topp M, Rosenthal M, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 39140289 · NCT05577416 (AB-218-IIT-201) · Astrocytoma

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Thu, 14 May 2026 22:31:59 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).